老药新用抗耐药细菌感染的研究进展

发布时间：2018-05-22 18:00

本文选题：感染 + 老药新用　；参考：《中国抗生素杂志》2017年05期

【摘要】：抗生素应用到临床治疗已经有70多年的历史,由于抗生素的不合理使用乃至滥用,细菌耐药问题日益严重。然而,新型抗生素开发成本高、周期长且效益低,医药公司对新型抗生素的研究和开发缺乏兴趣,导致传统抗生素治疗面临严峻挑战。近年来有研究发现,一些已被批准用于临床或正在进行临床试验的非抗感染药物也有抗感染作用,如金诺芬、依布硒林和塞来昔布等。本文将对这些非抗感染药物抗感染作用的研究进展进行综述,以便为克服抗生素耐药提供新思路。
[Abstract]:Antibiotics have been used in clinical treatment for more than 70 years. Because of irrational use and even abuse of antibiotics, the problem of bacterial drug resistance is becoming more and more serious. However, the development cost of new antibiotics is high, the cycle is long and the efficiency is low. The lack of interest in the research and development of new antibiotics in pharmaceutical companies leads to the severe challenge of traditional antibiotic treatment. In recent years, it has been found that some non-infective drugs that have been approved for clinical use or are undergoing clinical trials also have anti-infective effects, such as Jinnofen, ebuselin and celecoxib. This article will review the research progress of the anti-infection effects of these non-infective drugs in order to provide new ideas for overcoming antibiotic resistance.
【作者单位】：分子疫苗学和分子诊断学国家重点实验室厦门大学;厦门大学附属中山医院;
【基金】：国家自然科学基金(No.81661138005) 福建省自然科学基金(No.2015J01345) 厦门大学校长基金(No.20720160060)
【分类号】：R96

【相似文献】